Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade

KERRY REYNOLDS, a MOLLY THOMAS, b MICHAEL DOUGAN b
Divisions of aOncology and bGastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA

ABSTRACT

Many human tumors are recognized by the adaptive immune system, but these spontaneous antitumor responses are typically inadequate to mediate regression. Blockade of immune regulatory “checkpoint” receptors such as cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death 1 can unleash antitumor immunity, resulting in tumor responses that can be durable. Alongside the enormous promise of immunotherapy for cancer, the immune dysregulation of checkpoint blockade has led to a plethora of new autoimmune adverse events. Hepatic toxicity occurs in 1%–17% of patients on immune checkpoint inhibitors, with the precise incidence dependent on both the drug used and the underlying malignancy. Hepatitis is most commonly a low-grade toxicity, but grade 3 and 4 hepatotoxicity does occur. Here we will answer frequently asked questions regarding immune-related hepatitis to assist in the recognition and management of this important condition.

KEY POINTS

• Immune related hepatitis is a potentially serious complication of checkpoint blockade.
• The differential for elevated liver function tests in patients on checkpoint blockade is broad.
• Diagnostic testing such as viral serologies, liver ultrasound, cross sectional imaging, and liver biopsy may help in the diagnosis of immune related hepatitis in select patients.
• Patients with underlying cirrhosis are an at risk population for whom current grading criteria may underestimate the severity of liver inflammation.
• Severe immune related hepatitis is best managed by a multi-disciplinary team that includes a hepatologist.
• Most patients with immune related hepatitis respond to corticosteroids, but a substantial fraction require treatment with a secondary immunosuppressive agent.

HEPATIC TOXICITIES

Many human tumors are recognized by the adaptive immune system due to their expression of mutated proteins (neoantigens) [1]. Despite this recognition, most spontaneous antitumor immune responses are likely insufficient to cause tumor regression. In part, failure to reject nascent tumors is due to expression of immune regulatory “checkpoint” receptors that inhibit responses from activated T cells [2]. Blocking these checkpoints can unleash antitumor immunity, resulting in tumor response.

Recently, an increasing number of immune checkpoint inhibitors have been U.S. Food and Drug Administration (FDA) approved to treat advanced malignancy, and these therapies have created a paradigm shift in oncology [3–9]. Antibodies against the inhibitory checkpoint receptors cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and its ligand programmed death-ligand 1 (PD-L1) have shown durable responses in a subset of patients [3–9]. Immunotherapy for cancer has enormous promise, but the immune dysregulation induced by these therapies can also lead to adverse events that resemble autoimmune disease [10]. Immune-related adverse events (irAEs) most often affect the skin, gastrointestinal tract and liver, endocrine organs, and lung. The predictors that determine risk for irAEs are not well understood, nor is the relationship between these risks and those that predispose to “sporadic” autoimmunity. This new era of drug development may provide a window into the biology of these regulatory receptors, as well as insights into the onset and progression of sporadic autoimmune disease [11].

Correspondence: Michael Dougan, M.D., Ph.D., Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, 55 Fruit St., Blake 4, Boston, Massachusetts 02114, USA. Telephone: 617-726-3527; e-mail: mldougan@partners.org Received March 20, 2018; accepted for publication May 8, 2018; published Online First on May 31, 2018. http://dx.doi.org/10.1634/theoncologist.2018-0174

The Oncologist 2018;23:991–997 www.TheOncologist.com ©AlphaMed Press 2018
Hepatic toxicity is reported to occur in 1%–17% of patients on immune checkpoint inhibitors [5, 12]. The incidence varies with class of drug and appears to be synergistic in combination therapy targeting both CTLA-4 and PD-1. Hepatitis is most commonly a low-grade toxicity, but grade 3 and 4 hepatotoxicity does occur; similar to the overall incidence, severe hepatotoxicities are also substantially more common in patients on dual checkpoint blockade. Here we will answer a number of frequently asked questions regarding immune-related hepatitis (irH) to assist in the recognition and management of this condition.

**Case Vignette**

A 66-year-old woman with a history of hypertension, hyperlipidemia, and melanoma with pulmonary metastases received eight cycles of pembrolizumab and was transitioned to ipilimumab after she had documented disease progression. Her transaminases, which were normal prior to starting therapy, increased threefold 3 weeks after initiating ipilimumab. Therapy was held for Ast 170, Alt 488, alk phos 157, and Tbili 0.7. An abdominal ultrasound showed mildly echogenic liver parenchyma with patent hepatic vasculature and no evidence of abdominal metastases. Labs were notable for a normal serum IgG, Anti-Nuclear Antibody (ANA) 1:40, anti-smooth muscle antibody 1:80, antimitochondrial antibody 1:40, and no serologic evidence of acute or chronic viral hepatitis. Due to rising liver chemistries, she was admitted to the hospital and underwent a percutaneous liver biopsy that demonstrated lobular hepatitis with lymphohistiocytic inflammation and hepatocyte injury. She was started on intravenous (IV) methylprednisolone 1 mg/kg b.i.d. and later discharged on an oral prednisone taper. Although her liver chemistries initially improved on oral prednisone, her transaminases later rose during her steroid taper, and she was started on azathioprine 50 mg. Over the course of the next month, her liver chemistries completely normalized on prednisone and azathioprine.

**What is an Adequate Assessment Before Starting a Patient on Immunotheapy?**

A patient history (noting autoimmune, infectious, or organ-specific disease) is recommended prior to starting a patient on an immune checkpoint inhibitor [13]. Given the possibility of hepatic toxicity, the baseline assessment should include a detailed history of alcohol use, concomitant medications including acetaminophen, and herbal supplements.

During the pretreatment physical exam, one should look for signs of advanced liver disease including the presence of spider angioma, palmar erythema, gynecomastia, ascites, caput medusa, splenomegaly, or jaundice. Although potentially suggestive of advanced liver disease, these findings should be interpreted in the context of the patient’s underlying malignancy and other known chronic diseases.

Blood tests to consider include complete blood count, comprehensive metabolic panel, thyroid-stimulating hormone, Hemoglobin A1c (HbA1c), free thyroxine (T4), creatine kinase (CK), and an infectious disease screen with hepatitis B virus surface antigen (HBsAg), surface antibody and core antibody (HBsAb), hepatitis C virus antibody (HBCab), cytomegalovirus antibody (HCVAb), CMV antibody, T-spot test, human immunodeficiency virus testing (HIV), and a fasting lipid profile [13]. Liver chemistries should be drawn at baseline and at the time of each immunotherapy cycle. Elevated aminotransferase levels are most often the only indication of irH.

Baseline disease assessment with imaging is standard to evaluate disease burden in the liver for many malignancies. If abdominal imaging obtained as part of cancer staging is suggestive of underlying cirrhosis, confirmation of the diagnosis by liver biopsy or hepatic elastography (in patients without hepatic metastases) should be considered, although these tests to not necessarily need to be completed prior to initiation of therapy. Patients with underlying cirrhosis may benefit from more careful monitoring or earlier involvement of hepatology if they develop changes in liver chemistries during immunotherapy treatment.

**What Hepatic Immune-Related Adverse Events Have Been Reported and How Do They Present?**

There is marked variability in the clinical and histopathologic presentation of irH. Patients can be asymptomatic, present with nonspecific symptoms such as fever and fatigue, or have rapid progression and fulminant disease [14]. Asymptomatic elevations in the transaminases is the most common initial presentation [15].

Clinical trials have classified hepatic toxicity with a range of terminology. Categories include elevated alkaline phosphatase or aspartate aminotransferase, increased transaminases, or hepatitis. Although the incidence of severe toxicity is infrequent with single-agent therapy, it seems to be synergistic in patients on combination immune checkpoint inhibitors (Table 1). The highest rate of severe hepatic toxicity was seen in a combination halted for further development, dacarbazine with ipilimumab, which reported grade 3/4 alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) rates over 17% [21].

The Common Terminology Criteria for Adverse Events (CTCAE) is currently used to categorize the severity of immune-related adverse events (Table 2). Importantly, these criteria were created for patients on chemotherapy and therefore can underestimate the severity of inflammatory hepatitis. A quantitative increase in liver chemistries is not the sole marker for imminent severe disease. Of note, in sporadic autoimmune hepatitis, the level of transaminases does not always correlate with histologic extent of injury, particularly in the setting of hepatic fibrosis [22].

In addition, the CTCAE simplifies diverse pathologies. As a result, one could misclassify the severity of illness, missing more severe disease with lower liver chemistries; therefore, a grading system specifically for immuno-oncology needs to be considered. In lieu of this, at our institution, we consider any sign or symptom of liver failure or progressive rise in bilirubin grade 3 disease, and we consider alkaline phosphatase an independent classifier of grade, as alkaline phosphatase can be a leading indicator of biliary obstruction or inflammation [23]. Clinical features of concern include a rapidly rising alkaline phosphatase, coagulopathy, development of hepatic encephalopathy (mild confusion or asterixis to coma), ascites, or other symptoms of liver disease (pruritis, jaundice, petechiae, unexplained lactic acidosis).

Patients with underlying cirrhosis are a vulnerable population in which the CTCAE also likely underestimates the underlying disease severity. This is now more relevant after the FDA approval of nivolumab for patients with hepatocellular...
carcinoma following sorafenib [18]. The CTCAE grading criteria may not be adequate in patients with cirrhosis who have severe hepatitis, or tumor pseudo-progression, is a less common cause of liver-related pain.

Right-upper-quadrant pain is a rare presentation for irH and can indicate biliary obstruction, which would necessitate further investigation. Rapid distention of the liver capsule in the setting of severe hepatitis, or tumor pseudo-progression, is a less common cause of liver-related pain. Because checkpoint blockade can lead to multiple inflammatory toxici ty simultaneously, patients with hepatitis and abdominal pain should also be investigated for concurrent inflammatory pathology within the gastrointestinal tract [11].

What is the General Time of Onset of Hepatic irAEs?

The median onset of transaminase elevation is approximately 6–14 weeks after starting ICI treatment [10, 14, 24–26]. However, median time to onset appears variable depending on underlying malignancy and type of drug. Timing of onset of hepatitis after nivolumab in lung cancer (median 25 weeks, range 4–31) differs from melanoma (median 4 weeks, range 1–23 weeks) [27] and is longer than median onset with pembrolizumab (median 19 weeks, range 3–93) [27]. In our experience, hepatitis can also become unmasked in the setting of a steroid taper for other immune-related adverse events. Because of the range of reported presentations, we do not feel that timing of onset is useful diagnostically to distinguish checkpoint blockade-induced hepatitis from other potential causes of transaminase elevation in these patients, and it did not figure into the evaluation in the case presented.

Table 1. Severity of liver toxicity by drug, by cancer type

| Cancer type and drug | Hepatitis* | AST | ALT |
|----------------------|------------|-----|-----|
|                      | All Gr     | Gr 3/4 | All Gr | Gr 3/4 | All Gr | Gr 3/4 |
| Melanoma             |            |       |       |       |       |       |
| Pembrolizumab [12]   | 5/277 (1.8%) | 5/277 (1.8%) | 12/313 (3.8%) | 3/313 (1%) | 12/313 (3.8%) | 4/313 (1.3%) |
| Nivolumab [5]        |            |       |       |       |       |       |
| every 2 wk           |            |       |       |       |       |       |
| Ipilimumab [12]      | 3/256 (1.2%) |       | 11/311 (3.5) | 2/313 (0.6%) | 12/311 (3.9%) | 5/311 (1.6%) |
| Ipilimumab + Nivolumab | 48/313 (15.3%) | 19/313 (6.1%) | 55/313 (17.6%) | 26/313 (8.3%) | |
| Colon cancer dMMR/MSI-H | 3 mg/kg every 2 wk plus ipilimumab | 1/38 (2.6%) | 1/38 (2.6%) | |
| Colon cancer dMMR/MSI-H | 1 mg/kg every 12 wk | |
| Nivolumab 3 mg/kg    | 10/48 (21%) | 5/48 (10%) | 7/48 (15%) | 3/48 (6%) | |
| every 2 wk [18]     |            |       |       |       |       |       |
| Nivolumab 3 mg/kg    | 5/74 (7%) | 3/74 (4%) | 1/74 (1%) | |
| every 2 wk [19]     |            |       |       |       |       |       |
| Gastric cancer       | 5/330 (1.5%) | 1/330 (grade <1%) | 11/330 (3%) | 2/330 (1%) | 7/330 (2%) | 1/330 (<1%) | |

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; dMMR, deficient mismatch repair; Gr, grade; MSI-H, microsatellite instability high; wk, week.

Table 2. Grading of liver function tests

| Liver Test              | Grade 1       | Grade 2       | Grade 3       | Grade 4       |
|------------------------|---------------|---------------|---------------|---------------|
| Alkaline phosphatase   | >ULN–2.5 × ULN (<200) | >2.5–5.0 × ULN (200–400) | >5.0–20.0 × ULN (>400) | >20.0 × ULN |
| Bilirubin              | >ULN–1.5 × ULN (<100) | >1.5–3.0 × ULN (100–200) | >3.0–10.0 × ULN (>200) | >10.0 × ULN |
| Aspartate aminotransferase | >ULN–3.0 × ULN (<100) | >3.0–5.0 × ULN (100–200) | >5.0–20.0 × ULN (>200) | >20.0 × ULN |
| Alanine aminotransferase | >ULN–3.0 × ULN (<100) | >3.0–5.0 × ULN (100–200) | >5.0–20.0 × ULN (>200) | >20.0 × ULN |

Adapted from Common Terminology Criteria for Adverse Events, ULN based on institutional reference lab ranges; suggested values in parentheses are based on ideal values for an otherwise healthy individual. Abbreviations: ULN, upper limit of normal.

c AlphaMed Press 2018

www.TheOncologist.com
previous chemotherapy, and (e) use of other hepatotoxic drugs, including herbal medications, acetaminophen, and other medications purchased over the counter.

Patients typically present without symptoms or with non-specific symptoms such as fatigue. Pruritis can occur in association with cholestatic hepatitis but should raise the suspicions for an alternative etiology such as drug-induced liver injury. Because of the risk of overlapping irAEs, many patients also present with symptoms unrelated to their hepatitis, but related to their underlying therapy, such as nausea, diarrhea, or joint pain.

Hepatitis from checkpoint blockade typically has no physical exam findings. Signs of severe liver injury on physical exam should be evaluated (asterixis, ascites, caput medusa, hepato-megaly, jaundice, scleral icterus). Fevers should prompt a workup for infection.

The differential for hepatitis in a patient with cancer on checkpoint blockade is broad, and alternative diagnoses should be carefully considered.

- Disease progression (or pseudoprogression).
- Acute infections (Epstein Barr Virus [EBV], CMV, hepatitis A/B/C, adenovirus), particularly in patients on immune suppression for previous irAE or other reasons.
- Drug-induced liver injury in any patient taking a new medication; this is one of the main diagnoses that can be assessed by liver biopsy. Common offenders include acetaminophen and acetaminophen combination medications (i.e., percocet), antibiotics, statins, targeted therapy, chemotherapy, nitrofurantoin, methyldopa, diclofenac, and herbs such as Sho-saiko-to. The NIH LiverTox website (https://livertox.nih.gov) provides up-to-date information on liver injury caused by prescription and nonprescription medications, herbs, and dietary supplements. For patients who appear systemically ill with elevated liver chemistries, fever, rash, eosinophilia, and lymphadenopathy, more severe drug reactions such as drug reaction with eosinophilia and systemic symptoms should be considered.
- Thromboembolism associated with metastatic cancer such as portal vein thrombosis, Budd Chiari syndrome, and hepatic sinusoidal obstruction syndrome. Hepatic ultrasound with dopplers to exclude clot should be considered with ≥grade 2 Liver Function Tests (LFTs).
- Shock liver has a sudden onset and rapid resolution without treatment; as hypotension is not always documented clinically, this diagnosis should be considered for all patients at risk for hepatic hypoperfusion.
- Alcohol-induced hepatitis should be specifically investigated by history and potential blood alcohol testing in any patient with an AST/ALT ratio greater than 1.
- Myositis is an uncommon irAE but should be considered in patients with dramatic AST elevations relative to ALT and in patients presenting with muscle pain or severe fatigue.
- Immune-mediated hepatitis. Although a common cause of liver test elevations in patients on immunotherapy, treating a presumptive diagnosis without considering alternatives can expose patients to unnecessary risk.

Patients with serologic evidence of chronic infection with hepatitis B (HBsAg positive) or hepatitis C (HCV RNA positive) are at increased risk for worsening viral hepatitis in the setting of immune suppression, and the influence of checkpoint blockade on these infections is poorly understood. Viral hepatitis should be strongly considered in any chronically infected patient whose liver chemistries worsen during immunotherapy treatment or while on immunosuppressive medications. Patients with isolated HBsAb positivity with negative HBsAg are at extremely low risk for reactivation, although repeat HBsAg testing could be considered in these patients if they have elevations in their liver chemistries. Antiviral therapy is generally well tolerated for both hepatitis B and hepatitis C and may be indicated in some instances in conjunction with a hepatologist; these include patients with a high likelihood of long-term survival, those with evidence of substantial ongoing active viral hepatitis, and those for whom treatment with a Tumor Necrosis Factor (TNF)-α blocking biologic is otherwise indicated.

The utility of liver biopsies in patients with suspected irH is incompletely understood, and guidelines are based on expert opinion. Several pathologic subtypes have been described for patients with suspected hepatitis on checkpoint therapy. These include a “classic” panlobular lymphocytic hepatitis, zone 3 hepatitis with central vein damage and endothelial inflammation, cholangitis, bile duct injury, nonalcoholic steatohepatitis, and fibrin ring granulomas (with PD-1) [14, 24, 26]. These different histologic subtypes likely represent manifestations of distinct immune pathologies. Whether these distinct pathologies alter response to treatment is unknown, although clearly a substantial fraction of cases of checkpoint hepatitis do not respond to first-line corticosteroids.

At our institution, we perform biopsies on most patients with grade 3 or higher hepatitis and on selected patients with lower-grade complications. Factors that should be considered prior to obtaining a biopsy are the use of other potentially hepatotoxic medications in addition to immunotherapy, use of investigational combinations, presence of hepatic metastases, cholestatic hepatitis, failure to respond to corticosteroids, and bleeding risk. Image-guided percutaneous liver biopsy has a risk for subcapsular hemorrhage that is reported to be 0.8% – 1.7% in patients with normal coagulation and platelet counts, although the actual risk is operator dependent. Most subcapsular hemorrhages will resolve with supportive care, and mortality from these injuries is exceptionally low. For patients deemed at increased risk for percutaneous biopsy (i.e., those with coagulopathy, infection of the overlying skin, or large-volume ascites) and who have normal neck anatomy, a transjugular biopsy has a lower risk for serious complications (0.6%) and may be appropriate. In the case vignette, the patient presented with grade 3 hepatitis and we made the decision to confirm the diagnosis of irH prior to beginning steroids as she was a low-risk biopsy candidate, and we were able to obtain a biopsy shortly after presentation.

American Society of Clinical Oncology guidelines recommend consideration of liver autoantibody testing (Anti-Nuclear Antibody [ANA], Anti-Smooth Muscle Antibody [ASMA], and liver/kidney microsomes [LKM]) [28]. Sporadic autoimmune hepatitis occurs in two groups. Type 1 autoimmune hepatitis is classically characterized by ANA and/or ASMA circulating antibodies, although low titers of these autoantibodies markers ≤1:80 are common in other chronic liver diseases such as fatty liver disease. Type 2 autoimmune hepatitis is associated with antibodies to LKM. Positive autoantibodies are uncommon in irH, although in the case presented, ASMA was borderline.
### Table 3. Recommended hepatic workup

| Liver Test | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|------------|---------|---------|---------|---------|
| Ast and ALT | SITC/ESMO/ASCOC-NCCN: Continue ICU, check LFT 1–2 times weekly | SITC/ASCO-NCCN: | SITC/ASCO-NCCN: | SITC: |
|             | Hold ICU | Hold ICI | Hold ICI | Identical recommendations as in grade 3 |
|             | Check LFTs biweekly, workup with viral, autoimmune studies investigate new metastasis, clot | Review medications (statins, antibiotics, EtOH) | Workup—LFT, INR, albumin every 3 days, hepatitis A/B/C serology, hepatitis E PCR, anti-ANA/SMA/LKM/SLA/LP/ICI, iron studies, consider imaging | Monitor CMP every 1–2 days, corticosteroid 1–2 mg/kg/day. |
|             | Corticosteroid 0.5–1 mg/kg with at least 1-month taper | if rising on recheck, start oral prednisolone 1 mg/kg | ALT/AST with GGT, send HepB cAb, IgM, HepA IgM, HepC PCR. Consider infectious workup (EBV/CMV) especially in immune-compromised hosts. | SITC: If no improvement after 3 days, trial mycophenolate mofetil. |
|             | Resume ICI when LFTs are grade 1 and corticosteroid taper is 10 mg/day or less | If the biopsy is not diagnostic, for accelerated workup and symptom management. | ASCO-NCCN: If no improvement after 3 days, trial mycophenolate mofetil or azathioprine | ASCO-NCCN: If no improvement after 3 days, trial mycophenolate mofetil or azathioprine |
|             | SITC recommendations state liver biopsy is optional | If the biopsy is not diagnostic, for accelerated workup and symptom management. | If LFTs improve, taper over 4 weeks | If LFTs improve, taper over 4 weeks |
|             | ESMO | ESMO | ESMO | ESMO |
|             | Hold ICI | Stop ICI | Stop ICI | Stop ICI |
|             | Review medications (statins, antibiotics, EtOH) | Workup as in grade 2 with US with Doppler | Workup as in grade 2 with US with Doppler | Workup as in grade 2 with US with Doppler |
|             | Workup—LFT, INR, albumin every 3 days, hepatitis A/B/C serology, hepatitis E PCR, anti-ANA/SMA/LKM/SLA/LP/ICI, iron studies, consider imaging | ALT/AST <400 and nl bili/INR/albnum – oral prednisolone 1 mg/kg | ALT/AST >400 or raised bilirubin/INR/low albumin (IV methylprednisolone 2 mg/kg) | ALT/AST >400 or raised bilirubin/INR/low albumin (IV methylprednisolone 2 mg/kg) |
|             | If rising on recheck, start oral prednisolone 1 mg/kg | IV until grade 2, then oral with wean over 4 weeks | IV until grade 2, then oral with wean over 4 weeks | IV until grade 2, then oral with wean over 4 weeks |
|             | Once G1 wean over 2 weeks, once <10 mg, resume | Rechallenge only with GI involvement for G3. | Rechallenge only with GI involvement for G3. | Rechallenge only with GI involvement for G3. |
| Bilirubin    | Continue ICU | Our recommendation: Hold ICI | Our recommendation: Hold ICI | Our thoughts: If bili is elevated or symptoms, consider escalating the grade of toxicity (RUQ pain, edema/ascites, pruritus). Elevated INR, hepatic encephalopathy, new ascites is severe toxicity regardless of ALT/AST. If persistent grade 1, persist with additional workup |
| ALP         | Continue ICU | Our recommendation: Hold ICI | Our thoughts: If bili is elevated or symptoms, again consider escalating grade. For complete workup, recommend RUQ US with Doppler with consideration of cross-sectional imaging if there is concern for new metastatic disease, CK, confirm ALP elevation with GGT, send HepA Ab, HepB sAg/SAb/cAb, HepC Ab. If additional risk factors/exposures are present, send HepB cAb, IgM, HepA IgM, HepC PCR. Consider infectious workup (EBV/CMV) especially in immune-compromised hosts. Consider MRCP in patients with symptoms of biliary obstruction (RUQ pain, crampy pain with eating, ALP elevation) | Note, autoimmune serologies will not change management, and it is unclear if serologies are pathogenic in autoimmune hepatitis or if they are good biomarkers for patients that will respond to steroids |
|             | Our thoughts: If bili is elevated or symptoms, again consider escalating grade. For complete workup, recommend RUQ US with Doppler with consideration of cross-sectional imaging if there is concern for new metastatic disease, CK, confirm ALP elevation with GGT, send HepA Ab, HepB sAg/SAb/cAb, HepC Ab. If additional risk factors/exposures are present, send HepB cAb, IgM, HepA IgM, HepC PCR. Consider infectious workup (EBV/CMV) especially in immune-compromised hosts. Consider MRCP in patients with symptoms of biliary obstruction (RUQ pain, crampy pain with eating, ALP elevation) | Note, autoimmune serologies will not change management, and it is unclear if serologies are pathogenic in autoimmune hepatitis or if they are good biomarkers for patients that will respond to steroids |

Adapted from published guidelines [13, 24, 32–34] and Common Terminology Criteria for Adverse Events.

Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, anti-nuclear antibody; ASCO, American Society of Clinical Oncology; AST, aspartate aminotransferase; CK, creatine kinase; CMP, comprehensive metabolic panel; CMV, cytomegalovirus; EBV, Epstein Barr virus; ESMO, European Society for Medical Oncology; ETOH, ethyl alcohol; GGT, Gamma-glutamyl transferase; GI, gastrointestinal; ICI, immune checkpoint inhibitor; ICU, intensive care unit; INR, international normalized ratio; IV, intravenous; LCl, liver cytosol 1; LFT, liver function tests; LKM, liver kidney microsome; LP, liver-pancreas; MRCP, magnetic resonance cholangiography; NCCN, National Comprehensive Cancer Network; PCR, polymerase chain reaction; RUQ, right upper quadrant; SIRT, selective internal radiation therapy; SITC, society for immunotherapy of cancer; SLA, soluble liver antigen; SMA, smooth muscle antibody; US, ultrasound.

©AlphaMed Press 2018
positive. The presence (or absence) of these antibodies in patients with irH does not change management, and their clinical significance in this population is unknown.

What is the Typical Treatment?
Treatment of patients with severe liver disease is complex and is managed best through a multidisciplinary team that includes practitioners who are familiar with the underlying cancer and the immunotherapeutic agent, as well as experts in hepatology and liver pathology (Table 3). This approach may increase the chance that alternative diagnoses will be captured and can improve symptomatic management.

Corticosteroids are first-line therapy for suspected or established irH. No trials have directly addressed corticosteroid dose, nor has the effectiveness of any corticosteroid regimen been clearly established. Most centers use steroid dosing regimens borrowed from the treatment of other irAEs associated with checkpoint blockade or from the treatment of spontaneous autoimmune hepatitis. For outpatients, we typically start by treating with prednisone 60 mg daily and taper slowly over a period of 2 months. For hospitalized patients, patients with grade 4 disease, or patients who incompletely respond to prednisone, we consider IV solumedrol 0.5–1 mg/kg b.i.d. For patients who incompletely respond to corticosteroids, or who flare during a steroid taper, several other agents have been reported to have efficacy in the second line. These include azathioprine (1–2 mg/kg), mycophenolate mofetil (500–1,000 mg b.i.d.), or tacrolimus (dosed based on blood trough levels targeting 8–10). Importantly, before using azathioprine, the FDA recommends testing for Thiopurine S-methyltransferase (TPMT) genotype or enzyme function, as patients with decreased TPMT activity are at high risk for developing life-threatening irAEs that are steroid nonresponsive, such as checkpoinct colitis [29].

Infliximab is associated with a rare syndrome of immune-mediated hepatitis and for this reason is not recommended as therapy for irH. Although given the rarity of this side effect, the presence of irH should not be considered an absolute contraindication to infliximab treatment in patients who develop other life-threatening irAEs that are steroid nonresponsive, such as checkpoint colitis [29].

What are Considerations with Using Steroids?
Corticosteroids are broadly immune suppressive, with a range of side effects, and the effect on antitumor immunity in patients is unknown. In animal models, corticosteroids clearly inhibit effective antitumor responses, but retrospective analyses of patients suggest that corticosteroid use is not associated with decreased overall survival compared with untreated patients [30]. We recommend avoiding empiric corticosteroid use until other diagnoses have been effectively excluded, provided this can be done rapidly. This approach limits steroid side effects, may improve antitumor responses, and may lead to more rapid recognition of the underlying problem. For example, transaminases may fall in drug-induced liver injury while holding specific medications, but without any biopsy/confirmation, this could be attributed to empiric corticosteroid use, leading to a prolonged corticosteroid course and possible re-exposure to the inciting medication.

What is the Prognosis?
Most patients with irH will have resolution of the hepatic injury with immune suppression, and the long-term prognosis appears to be good. This was the case with the patient presented above. Whether some subset of patients with prior irH remain at risk for complications in the future is unknown.

Importantly, we have minimal data on the risks and outcomes of irH in the setting of cirrhosis, and these patients should be managed cautiously and in conjunction with a hepatologist.

Who Can You Re-Treat?
Any patient with a diagnosis of hepatitis that is not directly related to checkpoint blockade could be considered for retreatment. Rapid resolution of transaminase elevations may point to specific etiologies and should be considered in retreatment decisions. Grade 1 hepatitis does not require discontinuation of treatment. Patients who develop hepatitis with treatment targeting one pathway (e.g., CTLA-4) are not necessarily going to develop irH from treatment targeting another pathway (PD-1/ PD-L1) [31]; however, retreatment of irH patients with drugs from the same class (i.e., nivolumab and pembrolizumab) is not recommended. At present, there are no therapies that have been tried concurrently with checkpoint blockade to suppress irH, but this is an attractive area for research.

CONCLUSION
The hepatic toxicities associated with checkpoint blockade are heterogeneous, with a wide range of underlying pathophysiologicals of which immune-mediated disease is a significant fraction, but far from the only etiology. Biopsy is the gold standard for diagnosis of liver disease and should be considered in any patient with changes in liver chemistries that would prompt changes in management. The incidence of irH varies with the class of drug and appears to be synergistic with combination therapy targeting CTLA-4 and PD-1. This is likely to be an increasing issue as more combination clinical trials begin, including those with chemotherapy or targeted therapy. Baseline assessments are essential, but even substantial underlying liver disease does not preclude treatment. Greater caution should be taken with patients who have cirrhosis or those with liver dysfunction prior to treatment. Diagnosing impending liver failure is challenging, and CTCAE does not accurately capture severity. Time to onset varies, so clinical suspicion must stay elevated. Even when the diagnosis of irH is clear, management strategies have not been optimized. Through collaborative efforts, we have an opportunity to characterize this disease far more completely, develop more tailored treatments, and establish more meaningful guidelines both for immune-mediated hepatotoxicity and potentially for sporadic autoimmune hepatitis.

ACKNOWLEDGMENTS
Funding was provided by National Institutes of Health Mentored Clinical Scientist Development Award 1K08DK114563-01.

©AlphaMed Press 2018
REFERENCES

1. Schumacher TN, Schreiber RD. Neoadtigens in cancer immunotherapy. Science 2015;348:69–74.
2. Baumeister SH, Freeman GJ, Dranoff G et al. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 2016;34:539–573.
3. Daud A, Ribas A, Robert C et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 2015;33(suppl 15):9005a.
4. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
5. Larkin J, Chiarion-Silven V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
6. Schadendorf D, Hodi FS, Robert C et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33(17):1889–1894.
7. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 2015;373:1627–1639.
8. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med 2015;373:123–135.
9. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–1813.
10. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev 2016;44:51–60.
11. Dougan M. Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract. Front Immunol 2017;8:1547.
12. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521–2532.
13. Puzanov I, Diab A, Abdallah K et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.
14. Kim KW, Ramaiya NH, Krajewski KM et al. Ipilimumab associated hepatitis: Imaging and clinicopathologic findings. Invest New Drugs 2013;31:1071–1077.
15. De Martin E, Michot JM, Papouin B et al. Characterization of liver injury induced by cancer immunotherapy using monoclonal immune checkpoint inhibitors. J Hepatol 2018 [Epub ahead of print].
16. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517–2526.
17. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54–66.
18. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342:1266–1271.
19. El-Khoueiry AB, Sangro B, Yau T et al. Nivolumab in patients with advanced hepatocellular carcinoma [CheckMate 040]: An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–2502.
20. Johnhalla M, Misraji J, Pratt DS et al. Ipilimumab-associated hepatitis: Clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 2015;39:1075–1084.
21. Chmiele KD, Suan D, Liddle C et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011;29:e237–e240.
22. Everett J, Srivastava A, Misraji J. Fibrin ring granulomas in checkpoint inhibitor-induced hepatitis. Am J Surg Pathol 2017;41:134–137.
23. Eigentler TK, Hassel JC, Borking C et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016;45:7–18.
24. Brahmer JR, Laczetti C, Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2018 [Epub ahead of print].
25. Mancini S, Amorotti E, Vecchio S et al. Infliximab-related hepatitis: Discussion of a case and review of the literature. Intern Emerg Med 2010;5:193–200.
26. Horvat TZ, Adel NG, Ding TO et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193–3198.
27. Pollack MH, Betof A, Dearden H et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018;29:250–255.
28. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387:1540–1550.
29. Hellmann MD, Rizvi NA, Goldman JW et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 022): Results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31–41.
30. Overman MJ, McDermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–1191.
31. Kang YK, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461–2471.
32. Haanen JBAG, Carbonnel F, Robert C et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl 4):iv119–iv142.
33. Cuzzubbo S, Javeri F, Tissier M et al. Neurology of immune checkpoint inhibitors: Review of the literature. Eur J Cancer 2017;73:1–8.
34. Spain L, Walls G, Julve M et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: A single centre experience and review of the literature. Ann Oncol 2017;28:377–385.